| MDL | MFCD00943251 |
|---|---|
| Molecular Weight | 406.31 |
| Molecular Formula | C20H21Cl2N3O2 |
| SMILES | O=C(C1=C2C3=CC=C(O)C=C3N=C1NCCN(C)C)C4=C2C=CC=C4.Cl.Cl |
TAS-103 dihydrochloride is a dual inhibitor of DNA topoisomerase I/II , used for cancer research.
|
Topoisomerase I |
Topoisomerase II |
TAS-103 is a dual inhibitor of DNA topoisomerase I/II. TAS-103 (0.1-10 μM) is active on CCRF-CEM cells, with an IC 50 value of 5 nM. TAS-103 (0.1 μM) significantly increases levels of topo IIα FITC immunofluorescence in individual CCRF-CEM cells [1] . TAS-103 (0.01-1 μM) is highly cytotoxic to Lewis lung carcinoma (LLC) cells, and Liposomal TAS-103 is almost as active as free TAS-103 [2] . TAS-103 inhibits the viability of HeLa cells, with an IC 50 of 40 nM. TAS-103 (10 μM) disrupts signal recognition particle (SRP) complex formation, and induces destabilization of SRP14 and SRP19 and its eventual degradation [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
TAS-103 (30 mg/kg, i.v.) causes significant tumor growth suppression in mice bearing Lewis lung carcinoma (LLC) cells, without obvious body weight loss, and the liposomal TAS-103 is more active than free TAS-103 [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
H 2 O : 5 mg/mL ( 12.31 mM ; ultrasonic and warming and heat to 60°C)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4612 mL | 12.3059 mL | 24.6117 mL |
| 5 mM | 0.4922 mL | 2.4612 mL | 4.9223 mL |
| 10 mM | 0.2461 mL | 1.2306 mL | 2.4612 mL |
Add each solvent one by one: PBS
Solubility: 3.57 mg/mL (8.79 mM); Clear solution; Need ultrasonic and warming and heat to 60°C